Report of Foreign Issuer (6-k)
May 29 2015 - 5:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2015
Commission File Number: 001-36596
___________________
TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)
96 Skyway Avenue
Toronto, Ontario M9W 4Y9
Canada
(Address of principal executive offices)
___________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form
40-F [X]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[ ]
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Trillium Therapeutics Inc. |
| |
|
| |
|
| Date: May 29, 2015 |
|
| |
By: /s/ James
Parsons
|
| |
Name: James Parsons |
| |
Title: Chief Financial Officer
|
2
EXHIBIT INDEX
May 29, 2015
British Columbia Securities Commission
Alberta Securities
Commission
The Manitoba Securities Commission
Ontario Securities
Commission
Nova Scotia Securities Commission
Via Sedar
NOTICE PURSUANT TO SUBSECTION 11.3 OF
NATIONAL
INSTRUMENT 51-102 (“NI 51-102”)
CONTINUOUS DISCLOSURE OBLIGATIONS
Pursuant to the requirements set out in subsection 11.3 of NI
51-102, the undersigned hereby gives notice of the results of voting from the
May 27, 2015 Annual Meeting of Shareholders of Trillium Therapeutics
Inc.
The shareholders of the Corporation voted to elect the
following individuals as directors of the Corporation until the next annual
meeting of shareholders or until their successors are elected or appointed, as
follows:
| Name |
For
|
% For
|
Withheld |
%
Withheld |
| Luke Beshar |
3,123,913 |
99.66
|
10,695 |
0.34
|
| Henry Friesen |
3,131,370 |
99.90
|
3,238 |
0.10
|
| Robert Kirkman |
2,874,070 |
91.69
|
260,538 |
8.31
|
| Michael Moore |
3,131,370 |
99.90
|
3,238 |
0.10
|
| Thomas Reynolds
|
3,124,071 |
99.66
|
10,537 |
0.34
|
| Niclas Stiernholm
|
3,131,370 |
99.90
|
3,238 |
0.10
|
| Calvin Stiller |
3,131,370 |
99.90
|
3,238 |
0.10
|
|
2. |
Appointment of Auditors
|
The shareholders of the Corporation voted, on a show of hands, to appoint Ernst& Young LLP, Chartered Accountants, as the auditor of the Company until the close of business at the next annual general meeting of shareholders, at a remuneration to
be fixed by the Directors.
| FOR IMMEDIATE RELEASE |
NASDAQ:TRIL |
| |
TSX: TR |
TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL
MEETING OF SHAREHOLDERS
Toronto, Ontario, May 29, 2015 – Trillium Therapeutics Inc.
(Nasdaq:TRIL; TSX: TR) an immuno-oncology company developing innovative
therapies for the treatment of cancer, today announced the voting results from
its 2015 annual meeting of shareholders held on May 27, 2015. The results of the
director elections were as follows:
| Nominee |
Votes For |
% of
Votes For |
Votes
Withheld |
% of Votes
Withheld |
| Mr.
Luke Beshar |
3,123,913 |
99.66 |
10,695 |
0.34 |
| Dr.
Henry Friesen |
3,131,370 |
99.90 |
3,238 |
0.10 |
| Dr.
Robert Kirkman |
2,874,070 |
91.69 |
260,538 |
8.31 |
| Dr.
Michael Moore |
3,131,370 |
99.90 |
3,238 |
0.10 |
| Dr.
Thomas Reynolds |
3,124,071 |
99.66 |
10,537 |
0.34 |
| Dr.
Niclas Stiernholm |
3,131,370 |
99.90 |
3,238 |
0.10 |
| Dr.
Calvin Stiller |
3,131,370 |
99.90 |
3,238 |
0.10 |
About Trillium Therapeutics:
Trillium Therapeutics Inc. is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on tumor cells in acute
myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully
human monoclonal antibody that blocks the activity of CD200, an
immunosuppressive molecule that is overexpressed by many hematopoietic and solid
tumors.
For more information visit: www.trilliumtherapeutics.com
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of the TSX) accepts responsibility for the adequacy
or accuracy of this release.
Contact:
Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
+1 416 595 0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
-2-
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Sep 2023 to Sep 2024
